Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in children and adolescents with homozygous familial hypercholesterolemia
2017-002297-39Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of alirocumab in homozygous familial hypercholesterolemia (HoFH), sponsored by Sanofi. Primary endpoint: Percent change in LDL cholesterol from baseline to Week 12. Started May 2018; status: completed.
02
Drugs
alirocumab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on 2017-002297-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002297-39.